Celldex Therapeutics, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2017 | — | $247.8M | $42.5M |
| Jun 2017 | — | $231.5M | $66.2M |
| Sep 2017 | — | $219.2M | $54.7M |
| Dec 2017 | — | $236.4M | $40.3M |
| Mar 2018 | — | $134.1M | $39.8M |
| Jun 2018 | — | $128.0M | $43.9M |
| Sep 2018 | — | $128.1M | $32.8M |
| Dec 2018 | — | $124.1M | $24.3M |
| Mar 2019 | — | $112.7M | $31.5M |
| Jun 2019 | — | $109.6M | $19.7M |
| Sep 2019 | — | $101.4M | $16.6M |
| Dec 2019 | — | $94.0M | $11.2M |
| Mar 2020 | — | $83.7M | $22.7M |
| Jun 2020 | — | $238.4M | $68.0M |
| Sep 2020 | — | $230.0M | $18.2M |
| Dec 2020 | — | $209.4M | $43.8M |
| Mar 2021 | — | $194.2M | $69.3M |
| Jun 2021 | — | $182.3M | $43.4M |
| Sep 2021 | — | $436.7M | $72.2M |
| Dec 2021 | — | $419.5M | $39.1M |
| Mar 2022 | — | $398.1M | $25.3M |
| Jun 2022 | — | $365.1M | $28.4M |
| Sep 2022 | — | $345.4M | $18.6M |
| Dec 2022 | — | $326.2M | $29.4M |
| Mar 2023 | — | $302.7M | $54.1M |
| Jun 2023 | — | $277.5M | $28.2M |
| Sep 2023 | — | $246.7M | $21.1M |
| Dec 2023 | — | $429.2M | $34.8M |
| Mar 2024 | — | $838.6M | $115.1M |
| Jun 2024 | — | $813.7M | $42.7M |
| Sep 2024 | — | $785.9M | $36.4M |
| Dec 2024 | — | $747.0M | $28.4M |
| Mar 2025 | — | $703.0M | $17.1M |
| Jun 2025 | — | $655.4M | $23.0M |
| Sep 2025 | — | $598.4M | $36.0M |
| Dec 2025 | — | $527.2M | $28.9M |
| Mar 2026 | — | $456.2M | $35.7M |
| Jun 2026 | — | $714.6M | $47.5M |